Global Antihypertensives Market

Antihypertensives Comprehensive Study by Type (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Vasodilators, Alpha Blockers, Renin Inhibitors, Others), Application (Hospitals, Specialty Clinics), Distribution Channel (Specialty Pharma Retail Stores, Hospital Phrama, Online Pharma) Players and Region - Global Market Outlook to 2026

Antihypertensives Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Antihypertensives Market Scope
Hypertension is described as a persistent increase in blood pressure outside the normal limit. Hypertension is characterized as a systolic/diastolic pressure that is consistently greater than 140/90mmHg, according to the World Health Organization. Antihypertensives are a form of blood pressure medication (high blood pressure). Alternative treatments for people with hypertension include angiotensin conversion enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin-receptor blockers (ARBs), beta-blockers, and diuretics. Thiazide diuretics are the most known first-line antihypertensives in reducing morbidity and mortality among most patients with hypertension. However, antihypertensives have side effects, the most frequent of which include a constant dry cough, dizziness, taste disturbances, swollen knees, constipation, and rashes. The market for antihypertensives is observed to grow at increasing rate owing to multiple factors including the prevalence of Hypertension and emergence of advance therapeutic techniques.

The Antihypertensives market study is segmented by Type (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Vasodilators, Alpha Blockers, Renin Inhibitors and Others), by Application (Hospitals and Specialty Clinics) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States and German Players will contribute to the maximum growth of Global Antihypertensives market throughout the predicted period.

Pfizer Inc. (Uinted States), Novartis AG (Switzerland), Sanofi (France), Merck & Co., Inc. (Germany), Johnson & Johnson Services, Inc. (United States), AstraZeneca (United Kingdom), Daiichi Sankyo Company, Limited. (Japan) and Ranbaxy Laboratories (Sun Pharma) (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Boehringer Ingelheim International GmbH (Germany), Lupin (India), Actavis (United States) and Roche Holding AG (Switzerland).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Antihypertensives market by Type, Application and Region.

On the basis of geography, the market of Antihypertensives has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).


United States, Food and Drug Administration, “E12A Principles for Clinical Evaluation of New Antihypertensive Drugs” - Lays Out General Guidelines for Evaluating Novel Antihypertensive Drugs in Clinical Trials and Provides Core Criteria for Evaluating Antihypertensives That Are Agreed in All Three ICH Countries, But There Are Some Regional Variations. and European Society of cardiology, “2018 ESC/ESH Clinical Practice Guidelines for the Management of Arterial Hypertension” – Provides Standards for Classification, Administration and Dosage limitations for Anti-Hypertensive Drugs for the Management of Arterial Hypertension, Across the European Union.

Market Trend
  • Technical Progress in Healthcare Sector

Market Drivers
  • Prevalence of Hypertension
  • Demand for Non-pharmacological Therapy
  • Rising Healthcare Awareness

Opportunities
  • Heavy Investments in Healthcare Research & Development
  • Unexplored Markets

Restraints
  • Side Effects and Adverse Reactions

Challenges
  • Certain Regulatory Approval


Key Target Audience
Anti-Hypertensive Drug Manufactures, New Entrants and Investors, Anti-Hypertensive Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Diuretics
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Angiotensin Receptor Blockers (ARBs)
  • Beta Blockers
  • Vasodilators
  • Alpha Blockers
  • Renin Inhibitors
  • Others
By Application
  • Hospitals
  • Specialty Clinics
By Distribution Channel
  • Specialty Pharma Retail Stores
  • Hospital Phrama
  • Online Pharma

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Hypertension
      • 3.2.2. Demand for Non-pharmacological Therapy
      • 3.2.3. Rising Healthcare Awareness
    • 3.3. Market Challenges
      • 3.3.1. Certain Regulatory Approval
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Healthcare Sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antihypertensives, by Type, Application, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antihypertensives (Value)
      • 5.2.1. Global Antihypertensives by: Type (Value)
        • 5.2.1.1. Diuretics
        • 5.2.1.2. Angiotensin Converting Enzyme (ACE) Inhibitors
        • 5.2.1.3. Angiotensin Receptor Blockers (ARBs)
        • 5.2.1.4. Beta Blockers
        • 5.2.1.5. Vasodilators
        • 5.2.1.6. Alpha Blockers
        • 5.2.1.7. Renin Inhibitors
        • 5.2.1.8. Others
      • 5.2.2. Global Antihypertensives by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialty Clinics
      • 5.2.3. Global Antihypertensives by: Distribution Channel (Value)
        • 5.2.3.1. Specialty Pharma Retail Stores
        • 5.2.3.2. Hospital Phrama
        • 5.2.3.3. Online Pharma
      • 5.2.4. Global Antihypertensives Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Antihypertensives: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (Uinted States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson Services, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Daiichi Sankyo Company, Limited. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ranbaxy Laboratories (Sun Pharma) (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Antihypertensives Sale, by Type, Application, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antihypertensives (Value)
      • 7.2.1. Global Antihypertensives by: Type (Value)
        • 7.2.1.1. Diuretics
        • 7.2.1.2. Angiotensin Converting Enzyme (ACE) Inhibitors
        • 7.2.1.3. Angiotensin Receptor Blockers (ARBs)
        • 7.2.1.4. Beta Blockers
        • 7.2.1.5. Vasodilators
        • 7.2.1.6. Alpha Blockers
        • 7.2.1.7. Renin Inhibitors
        • 7.2.1.8. Others
      • 7.2.2. Global Antihypertensives by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialty Clinics
      • 7.2.3. Global Antihypertensives by: Distribution Channel (Value)
        • 7.2.3.1. Specialty Pharma Retail Stores
        • 7.2.3.2. Hospital Phrama
        • 7.2.3.3. Online Pharma
      • 7.2.4. Global Antihypertensives Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antihypertensives: by Type(USD Million)
  • Table 2. Antihypertensives Diuretics , by Region USD Million (2015-2020)
  • Table 3. Antihypertensives Angiotensin Converting Enzyme (ACE) Inhibitors , by Region USD Million (2015-2020)
  • Table 4. Antihypertensives Angiotensin Receptor Blockers (ARBs) , by Region USD Million (2015-2020)
  • Table 5. Antihypertensives Beta Blockers , by Region USD Million (2015-2020)
  • Table 6. Antihypertensives Vasodilators , by Region USD Million (2015-2020)
  • Table 7. Antihypertensives Alpha Blockers , by Region USD Million (2015-2020)
  • Table 8. Antihypertensives Renin Inhibitors , by Region USD Million (2015-2020)
  • Table 9. Antihypertensives Others , by Region USD Million (2015-2020)
  • Table 10. Antihypertensives: by Application(USD Million)
  • Table 11. Antihypertensives Hospitals , by Region USD Million (2015-2020)
  • Table 12. Antihypertensives Specialty Clinics , by Region USD Million (2015-2020)
  • Table 13. Antihypertensives: by Distribution Channel(USD Million)
  • Table 14. Antihypertensives Specialty Pharma Retail Stores , by Region USD Million (2015-2020)
  • Table 15. Antihypertensives Hospital Phrama , by Region USD Million (2015-2020)
  • Table 16. Antihypertensives Online Pharma , by Region USD Million (2015-2020)
  • Table 17. South America Antihypertensives, by Country USD Million (2015-2020)
  • Table 18. South America Antihypertensives, by Type USD Million (2015-2020)
  • Table 19. South America Antihypertensives, by Application USD Million (2015-2020)
  • Table 20. South America Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 21. Brazil Antihypertensives, by Type USD Million (2015-2020)
  • Table 22. Brazil Antihypertensives, by Application USD Million (2015-2020)
  • Table 23. Brazil Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 24. Argentina Antihypertensives, by Type USD Million (2015-2020)
  • Table 25. Argentina Antihypertensives, by Application USD Million (2015-2020)
  • Table 26. Argentina Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 27. Rest of South America Antihypertensives, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Antihypertensives, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 30. Asia Pacific Antihypertensives, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Antihypertensives, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Antihypertensives, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 34. China Antihypertensives, by Type USD Million (2015-2020)
  • Table 35. China Antihypertensives, by Application USD Million (2015-2020)
  • Table 36. China Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 37. Japan Antihypertensives, by Type USD Million (2015-2020)
  • Table 38. Japan Antihypertensives, by Application USD Million (2015-2020)
  • Table 39. Japan Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 40. India Antihypertensives, by Type USD Million (2015-2020)
  • Table 41. India Antihypertensives, by Application USD Million (2015-2020)
  • Table 42. India Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 43. South Korea Antihypertensives, by Type USD Million (2015-2020)
  • Table 44. South Korea Antihypertensives, by Application USD Million (2015-2020)
  • Table 45. South Korea Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 46. Taiwan Antihypertensives, by Type USD Million (2015-2020)
  • Table 47. Taiwan Antihypertensives, by Application USD Million (2015-2020)
  • Table 48. Taiwan Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 49. Australia Antihypertensives, by Type USD Million (2015-2020)
  • Table 50. Australia Antihypertensives, by Application USD Million (2015-2020)
  • Table 51. Australia Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Antihypertensives, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Antihypertensives, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 55. Europe Antihypertensives, by Country USD Million (2015-2020)
  • Table 56. Europe Antihypertensives, by Type USD Million (2015-2020)
  • Table 57. Europe Antihypertensives, by Application USD Million (2015-2020)
  • Table 58. Europe Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 59. Germany Antihypertensives, by Type USD Million (2015-2020)
  • Table 60. Germany Antihypertensives, by Application USD Million (2015-2020)
  • Table 61. Germany Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 62. France Antihypertensives, by Type USD Million (2015-2020)
  • Table 63. France Antihypertensives, by Application USD Million (2015-2020)
  • Table 64. France Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 65. Italy Antihypertensives, by Type USD Million (2015-2020)
  • Table 66. Italy Antihypertensives, by Application USD Million (2015-2020)
  • Table 67. Italy Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 68. United Kingdom Antihypertensives, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Antihypertensives, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 71. Netherlands Antihypertensives, by Type USD Million (2015-2020)
  • Table 72. Netherlands Antihypertensives, by Application USD Million (2015-2020)
  • Table 73. Netherlands Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 74. Rest of Europe Antihypertensives, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Antihypertensives, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 77. MEA Antihypertensives, by Country USD Million (2015-2020)
  • Table 78. MEA Antihypertensives, by Type USD Million (2015-2020)
  • Table 79. MEA Antihypertensives, by Application USD Million (2015-2020)
  • Table 80. MEA Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 81. Middle East Antihypertensives, by Type USD Million (2015-2020)
  • Table 82. Middle East Antihypertensives, by Application USD Million (2015-2020)
  • Table 83. Middle East Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 84. Africa Antihypertensives, by Type USD Million (2015-2020)
  • Table 85. Africa Antihypertensives, by Application USD Million (2015-2020)
  • Table 86. Africa Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 87. North America Antihypertensives, by Country USD Million (2015-2020)
  • Table 88. North America Antihypertensives, by Type USD Million (2015-2020)
  • Table 89. North America Antihypertensives, by Application USD Million (2015-2020)
  • Table 90. North America Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 91. United States Antihypertensives, by Type USD Million (2015-2020)
  • Table 92. United States Antihypertensives, by Application USD Million (2015-2020)
  • Table 93. United States Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 94. Canada Antihypertensives, by Type USD Million (2015-2020)
  • Table 95. Canada Antihypertensives, by Application USD Million (2015-2020)
  • Table 96. Canada Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 97. Mexico Antihypertensives, by Type USD Million (2015-2020)
  • Table 98. Mexico Antihypertensives, by Application USD Million (2015-2020)
  • Table 99. Mexico Antihypertensives, by Distribution Channel USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Antihypertensives: by Type(USD Million)
  • Table 109. Antihypertensives Diuretics , by Region USD Million (2021-2026)
  • Table 110. Antihypertensives Angiotensin Converting Enzyme (ACE) Inhibitors , by Region USD Million (2021-2026)
  • Table 111. Antihypertensives Angiotensin Receptor Blockers (ARBs) , by Region USD Million (2021-2026)
  • Table 112. Antihypertensives Beta Blockers , by Region USD Million (2021-2026)
  • Table 113. Antihypertensives Vasodilators , by Region USD Million (2021-2026)
  • Table 114. Antihypertensives Alpha Blockers , by Region USD Million (2021-2026)
  • Table 115. Antihypertensives Renin Inhibitors , by Region USD Million (2021-2026)
  • Table 116. Antihypertensives Others , by Region USD Million (2021-2026)
  • Table 117. Antihypertensives: by Application(USD Million)
  • Table 118. Antihypertensives Hospitals , by Region USD Million (2021-2026)
  • Table 119. Antihypertensives Specialty Clinics , by Region USD Million (2021-2026)
  • Table 120. Antihypertensives: by Distribution Channel(USD Million)
  • Table 121. Antihypertensives Specialty Pharma Retail Stores , by Region USD Million (2021-2026)
  • Table 122. Antihypertensives Hospital Phrama , by Region USD Million (2021-2026)
  • Table 123. Antihypertensives Online Pharma , by Region USD Million (2021-2026)
  • Table 124. South America Antihypertensives, by Country USD Million (2021-2026)
  • Table 125. South America Antihypertensives, by Type USD Million (2021-2026)
  • Table 126. South America Antihypertensives, by Application USD Million (2021-2026)
  • Table 127. South America Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 128. Brazil Antihypertensives, by Type USD Million (2021-2026)
  • Table 129. Brazil Antihypertensives, by Application USD Million (2021-2026)
  • Table 130. Brazil Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 131. Argentina Antihypertensives, by Type USD Million (2021-2026)
  • Table 132. Argentina Antihypertensives, by Application USD Million (2021-2026)
  • Table 133. Argentina Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 134. Rest of South America Antihypertensives, by Type USD Million (2021-2026)
  • Table 135. Rest of South America Antihypertensives, by Application USD Million (2021-2026)
  • Table 136. Rest of South America Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 137. Asia Pacific Antihypertensives, by Country USD Million (2021-2026)
  • Table 138. Asia Pacific Antihypertensives, by Type USD Million (2021-2026)
  • Table 139. Asia Pacific Antihypertensives, by Application USD Million (2021-2026)
  • Table 140. Asia Pacific Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 141. China Antihypertensives, by Type USD Million (2021-2026)
  • Table 142. China Antihypertensives, by Application USD Million (2021-2026)
  • Table 143. China Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 144. Japan Antihypertensives, by Type USD Million (2021-2026)
  • Table 145. Japan Antihypertensives, by Application USD Million (2021-2026)
  • Table 146. Japan Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 147. India Antihypertensives, by Type USD Million (2021-2026)
  • Table 148. India Antihypertensives, by Application USD Million (2021-2026)
  • Table 149. India Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 150. South Korea Antihypertensives, by Type USD Million (2021-2026)
  • Table 151. South Korea Antihypertensives, by Application USD Million (2021-2026)
  • Table 152. South Korea Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 153. Taiwan Antihypertensives, by Type USD Million (2021-2026)
  • Table 154. Taiwan Antihypertensives, by Application USD Million (2021-2026)
  • Table 155. Taiwan Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 156. Australia Antihypertensives, by Type USD Million (2021-2026)
  • Table 157. Australia Antihypertensives, by Application USD Million (2021-2026)
  • Table 158. Australia Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Antihypertensives, by Type USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Antihypertensives, by Application USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 162. Europe Antihypertensives, by Country USD Million (2021-2026)
  • Table 163. Europe Antihypertensives, by Type USD Million (2021-2026)
  • Table 164. Europe Antihypertensives, by Application USD Million (2021-2026)
  • Table 165. Europe Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 166. Germany Antihypertensives, by Type USD Million (2021-2026)
  • Table 167. Germany Antihypertensives, by Application USD Million (2021-2026)
  • Table 168. Germany Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 169. France Antihypertensives, by Type USD Million (2021-2026)
  • Table 170. France Antihypertensives, by Application USD Million (2021-2026)
  • Table 171. France Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 172. Italy Antihypertensives, by Type USD Million (2021-2026)
  • Table 173. Italy Antihypertensives, by Application USD Million (2021-2026)
  • Table 174. Italy Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 175. United Kingdom Antihypertensives, by Type USD Million (2021-2026)
  • Table 176. United Kingdom Antihypertensives, by Application USD Million (2021-2026)
  • Table 177. United Kingdom Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 178. Netherlands Antihypertensives, by Type USD Million (2021-2026)
  • Table 179. Netherlands Antihypertensives, by Application USD Million (2021-2026)
  • Table 180. Netherlands Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 181. Rest of Europe Antihypertensives, by Type USD Million (2021-2026)
  • Table 182. Rest of Europe Antihypertensives, by Application USD Million (2021-2026)
  • Table 183. Rest of Europe Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 184. MEA Antihypertensives, by Country USD Million (2021-2026)
  • Table 185. MEA Antihypertensives, by Type USD Million (2021-2026)
  • Table 186. MEA Antihypertensives, by Application USD Million (2021-2026)
  • Table 187. MEA Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 188. Middle East Antihypertensives, by Type USD Million (2021-2026)
  • Table 189. Middle East Antihypertensives, by Application USD Million (2021-2026)
  • Table 190. Middle East Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 191. Africa Antihypertensives, by Type USD Million (2021-2026)
  • Table 192. Africa Antihypertensives, by Application USD Million (2021-2026)
  • Table 193. Africa Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 194. North America Antihypertensives, by Country USD Million (2021-2026)
  • Table 195. North America Antihypertensives, by Type USD Million (2021-2026)
  • Table 196. North America Antihypertensives, by Application USD Million (2021-2026)
  • Table 197. North America Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 198. United States Antihypertensives, by Type USD Million (2021-2026)
  • Table 199. United States Antihypertensives, by Application USD Million (2021-2026)
  • Table 200. United States Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 201. Canada Antihypertensives, by Type USD Million (2021-2026)
  • Table 202. Canada Antihypertensives, by Application USD Million (2021-2026)
  • Table 203. Canada Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 204. Mexico Antihypertensives, by Type USD Million (2021-2026)
  • Table 205. Mexico Antihypertensives, by Application USD Million (2021-2026)
  • Table 206. Mexico Antihypertensives, by Distribution Channel USD Million (2021-2026)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antihypertensives: by Type USD Million (2015-2020)
  • Figure 5. Global Antihypertensives: by Application USD Million (2015-2020)
  • Figure 6. Global Antihypertensives: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Antihypertensives Share (%), by Country
  • Figure 8. Asia Pacific Antihypertensives Share (%), by Country
  • Figure 9. Europe Antihypertensives Share (%), by Country
  • Figure 10. MEA Antihypertensives Share (%), by Country
  • Figure 11. North America Antihypertensives Share (%), by Country
  • Figure 12. Global Antihypertensives share by Players 2020 (%)
  • Figure 13. Global Antihypertensives share by Players (Top 3) 2020(%)
  • Figure 14. Global Antihypertensives share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer Inc. (Uinted States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer Inc. (Uinted States) Revenue: by Geography 2020
  • Figure 18. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 21. Sanofi (France) Revenue: by Geography 2020
  • Figure 22. Merck & Co., Inc. (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co., Inc. (Germany) Revenue: by Geography 2020
  • Figure 24. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2020
  • Figure 26. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 28. Daiichi Sankyo Company, Limited. (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Daiichi Sankyo Company, Limited. (Japan) Revenue: by Geography 2020
  • Figure 30. Ranbaxy Laboratories (Sun Pharma) (India) Revenue, Net Income and Gross profit
  • Figure 31. Ranbaxy Laboratories (Sun Pharma) (India) Revenue: by Geography 2020
  • Figure 32. Global Antihypertensives: by Type USD Million (2021-2026)
  • Figure 33. Global Antihypertensives: by Application USD Million (2021-2026)
  • Figure 34. Global Antihypertensives: by Distribution Channel USD Million (2021-2026)
  • Figure 35. South America Antihypertensives Share (%), by Country
  • Figure 36. Asia Pacific Antihypertensives Share (%), by Country
  • Figure 37. Europe Antihypertensives Share (%), by Country
  • Figure 38. MEA Antihypertensives Share (%), by Country
  • Figure 39. North America Antihypertensives Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (Uinted States)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Merck & Co., Inc. (Germany)
  • Johnson & Johnson Services, Inc. (United States)
  • AstraZeneca (United Kingdom)
  • Daiichi Sankyo Company, Limited. (Japan)
  • Ranbaxy Laboratories (Sun Pharma) (India)
Additional players considered in the study are as follows:
Boehringer Ingelheim International GmbH (Germany) , Lupin (India) , Actavis (United States) , Roche Holding AG (Switzerland)
Select User Access Type

Key Highlights of Report


Apr 2021 246 Pages 89 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antihypertensives Market Quantitative research analysis
Global Antihypertensives Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Antihypertensives Market Report?

Have a Query? Click Here

Other Related Reports

Dysmenorrhea Treatment Comprehensive Study by Application (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Hormonal Therapy), Drug Used (Ibup...
$ 3450
Silk Protein Comprehensive Study by Type (Fibroin, Sericin), Nature (Recyclable, Biodegradable, Biocompatible, Others), Industry Verticals (Cosmetics, Personal Care, Medical, Others), Sales Channel (...
$ 3500
Alectinib Drugs Comprehensive Study by Application (Hospitals, Clinics, Others), Capacity (1 Capsule, 140 Capsules, 28 Capsules, 26 Capsules), End Use (Unresectable NSCLC, Advanced NSCLC, Recurrent N...
$ 3500
Protein Stability Analysis Comprehensive Study by Type (Reagents and Assay Kits, Instruments, Consumable and Accessories, Software), Technique (Chromatography, Spectroscopy, Surface Plasma Resonance ...
$ 3750
Aerosols Budesonide Comprehensive Study by Application (Hospitals, Specialty Clinics, Over-the-Counter (OTC)), Distribution Channel (Online (E-Commerce Websites, Third Party Websites), Offline (Retai...
$ 3750
Oral Osmotic Laxative Comprehensive Study by Drug (Sodium sulfate, Magnesium carbonate, Magnesium citrate, Lactitol, Mannitol), Form (Powder, Injectable, Syrup, Others), End Use (Over-the-Counter (OT...
$ 3450